紫杉醇加醛氢叶酸、5-FU双周疗法治疗CAF方案耐药晚期乳腺癌临床观察  

Clinical Observision of Semimonthly Regimen for Paclitaxel Combined with 5-fluorouracil/leucovorin 48-hour Continuouse Infusion in Treatment of Advanced Breast Cancer Which Resistence CAF Regimen

作　　者：赵九军 侯宝忠[2] 李振清 何忠杰 

机构地区：[1]黑龙江省大庆市油田总医院肿瘤治疗中心,163001 [2]大庆市第四医院

出　　处：《医学研究杂志》2006年第6期44-46,共3页Journal of Medical Research

摘　　要：目的研究紫杉醇加醛氢叶酸、(5-FU)48h持续静脉滴注双周疗法治疗CAF方案耐药的晚期乳腺癌临床应用价值。方法80例晚期乳腺癌患者经过CAF治疗化疗无效,接受紫杉醇加醛氢叶酸、5-FU方案化疗,紫杉醇95mg/m2,静脉滴注,d1;LV200mgd1,静脉滴注,随后5-FU3g/m2,加入输液泵中静脉持续滴注48h,两周为1个周期;至少治疗4个周期。结果80例中CR9例,PR26例,SD32例,PD13例,总有效率43.8%(35/80)。中位缓解期8个月(2～27个月),中位生存期16.7个月(3～34个月)。紫杉醇加醛氢叶酸、(5-FU)48h持续静脉滴注方案对乳腺癌软组织、肺、胸膜、骨、肝转移的有效率分别为46.7%(21/45)、38.5%(5/13)、31.3%(5/16)、40%(4/10)和20%(2/10)。结论紫杉醇加醛氢叶酸、(5-FU)48h持续静脉滴注双周疗法治疗CAF方案耐药的晚期乳腺癌疗效好,毒副反应低,是治疗CAF方案耐药的晚期乳腺癌较理想的方案之一。Objective To study the clinical application value of advanced breast cancer which resistence CAF regimen, treated with semimonthly regimen for paclitaxel combined with 5 - fluomuracil/leucovorin 48 - hour continuouse infusion. Methods 80 paients with CAF - regimen -resistant ABC were treated with paclitaxel combined with 5 - fluomuracil/leucovorin continuouse infusion, paclitaxel 95mg/m^2, d1, LV 200mg, d1, 5 - fluorouracil 3g/m^2, continuouse infusion for 48 hours with infusion pump.every cycle lasted 2 weeks, at least 4 cycles.Results Of 80 patients, there were 9 complete and 26 partial responses, 32 cases remained stable and 13 progressive. The overall response rate of 43.8% .The median time to progression was 8 months.The median survival time was 16.7 months, the patients with soft tissue, lung, pleura, bone, liver obtainedresponse rat was46.7% （21/45）, 38.5% （5/13）, 31.3% （5/16）, 40% （4/10）, 20% （2/10） .Conclusions semin^ntlfiy regimen for paclitaxel combined with 5 - fluomuraeil/leucovorin 48 - hour continuouse infusion is effective and acceptable toxicity, could be considered as one of the standard chemotherapy for advanced breast cancer which resistence CAF regimen.

关 键 词：紫杉醇 醛氢叶酸 5-FU 48h持续静脉滴注 双周疗法 CAF方案耐药 晚期乳腺癌 

分 类 号：R739.910.5[医药卫生—肿瘤] R737.9[医药卫生—临床医学]